Virax Biolabs Group Ltd. Class A (VRAX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Virax Biolabs Group Ltd. has launched ImmuneSelect, a new suite of immune profiling solutions aimed at understanding adaptive immunity and post-viral syndromes like Long COVID. The portfolio, introduced at the ESCMID Global 2024 Congress, includes various tools for research use, such as peptide pools and recombinant antibodies, to assess and monitor T-Cell functions. This marks a significant step towards the eventual commercialization of their ViraxImmune T-Cell diagnostic platform.
For further insights into VRAX stock, check out TipRanks’ Stock Analysis page.